Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.

Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW.

Leuk Lymphoma. 2012 May;53(5):830-5. doi: 10.3109/10428194.2011.631637. Epub 2011 Dec 6.

2.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

PMID:
24432894
3.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT).

Biol Blood Marrow Transplant. 2012 May;18(5):788-93. doi: 10.1016/j.bbmt.2011.10.010. Epub 2011 Oct 17.

4.

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P.

Cancer. 2015 Jan 15;121(2):226-33. doi: 10.1002/cncr.29023. Epub 2014 Sep 9.

5.

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J.

Am J Hematol. 2013 Oct;88(10):890-4. doi: 10.1002/ajh.23524. Epub 2013 Aug 1.

6.

Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.

Villa D, Crump M, Keating A, Panzarella T, Feng B, Kuruvilla J.

Ann Oncol. 2013 Jun;24(6):1603-9. doi: 10.1093/annonc/mdt029. Epub 2013 Feb 20.

PMID:
23425946
7.

Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.

Madsen C, Pedersen MB, Vase MØ, Bendix K, Møller MB, Johansen P, Jensen BA, Jensen P, Munksgaard L, Brown PD, Segel EK, d'Amore FA.

Ann Oncol. 2015 Feb;26(2):393-9. doi: 10.1093/annonc/mdu537. Epub 2014 Nov 18.

PMID:
25411416
8.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B.

J Clin Oncol. 2012 Dec 20;30(36):4462-9. doi: 10.1200/JCO.2012.41.9416. Epub 2012 Oct 22.

9.

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.

Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW.

Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20.

10.

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM.

Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876.

PMID:
20496994
11.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
12.

Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.

Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, de Lima M, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. doi: 10.1016/j.bbmt.2015.06.007. Epub 2015 Jun 16.

13.

Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.

Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramirez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO cooperative group).

Ann Oncol. 2010 Sep;21(9):1891-7. doi: 10.1093/annonc/mdq035. Epub 2010 Mar 15.

PMID:
20231299
14.

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2072-5. doi: 10.1016/j.bbmt.2014.07.028. Epub 2014 Jul 29.

15.

Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.

Kruger PC, Cooney JP, Turner JH.

Cancer Biother Radiopharm. 2012 Nov;27(9):552-60. doi: 10.1089/cbr.2012.1275. Epub 2012 Oct 12.

PMID:
23062193
16.

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.

Stover DG, Reddy VK, Shyr Y, Savani BN, Reddy N.

Bone Marrow Transplant. 2012 Jan;47(1):82-7. doi: 10.1038/bmt.2011.29. Epub 2011 Feb 28.

PMID:
21358691
17.

Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.

Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A.

Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26.

PMID:
24274082
18.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.

19.
20.

High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.

Leuk Lymphoma. 2006 Aug;47(8):1545-52.

PMID:
16966265

Supplemental Content

Support Center